

HBM Holdings 2022 Investor Day



CONTENTS

01 Opening Remarks

02 Harbour Therapeutic: Innovation Empowered Growth

03 Nona Biosciences: Platform-based Enabler from Idea to IND

04 Closing Remarks






HBM's Global Innovation with Robust Discovery Engines

Dr. Jingsong Wang




Founder, Chairman of the Board and Chief Executive Officer
Harbour BioMed



Continuously Advancing Innovative Portfolio and Platform Technology



Highly Innovative and Differentiated Global Pipeline

Project	Target	Indication	Commercial Rights	Status						
				Discovery	Pre-Clinical	IND	Phase I	Phase II	Phase III	BLA
Porustobart (HBM4003)	CTLA-4 ¹	Solid Tumors ^a	Global	Monotherapy Ph 1b/2						
		Solid Tumors ^b		Combo with PD-1 Ph 1b/2						
		Solid Tumors ^c		Combo with PD-1/PD-1+Chemo Ph 1						
HBM7008	B7H4×4-1BB	Solid Tumors	Global	Ph 1 ²						
HBM7022	CLDN18.2×CD3	Solid Tumors	Global Out-license	AstraZeneca 						
HBM7004	B7H4×CD3	Solid Tumors	Global							
HBM9027	PD-L1×CD40	Solid Tumors	Global							
HBM9378	TSLP	Asthma	Global	Ph 1 						
HBM9033	MSLN ADC	Solid Tumors	Global							
HBM1022	CCR8	Solid Tumors	Global	US IND filing expected in Q1 2023						
HBM1020	B7H7	Solid Tumors	Global	US IND filing expected in 2022						
HBM1007	CD73	Solid Tumors	Global	US IND filing expected in 2022						
HBM1047	CD200R1	Solid Tumors	Global							
HBM9014	LIFR	Solid Tumors	Global	Yinuoke 						

1. HBM4003 is a next-gen anti-CTLA-4 antibody with enhanced ADCC for Treg depletion
 2. HBM7008 completed Phase I FPF in Australia in May, US IND clearance and China IND approval in June 2022

a. Melanoma, HCC, RCC and Other Advanced Solid Tumors
 b. Melanoma, HCC, NEC/NET and Other Advanced Solid Tumors
 c. NSCLC and Other Advanced Solid Tumors



Global Collaborations to Maximize the Value of Technologies and Assets



50+ Partners



200+ Projects



10+ Clinical Stage

Technology Licensing

MDAnderson
Cancer Center

celsius

Lilly

BeiGene

Pfizer

Innovent
信达生物制药

Program-based collaborations

AstraZeneca

abbvie

VIR

moderna

Dragonfly
THERAPEUTICS

Mount
Sinai

Erasmus MC
University Medical Center Rotterdam

Dana-Farber
Cancer Institute

LCB
LegoChemBio

COMPASS
THERAPEUTICS

Boston
Children's
Hospital
Until every child is well

恩凯赛药
NK CELLTECH

DualityBio
映恩生物

NL Health~Holland
SHARED CHALLENGES, SMART SOLUTIONS

THE
WISTAR
INSTITUTE

BioMap 百图生科

HBMAT






Harbour BioMed: Leading Next-Gen Biotherapeutic Innovation



Lead Next-Gen IO Therapeutics

- Global Innovation
- Worldwide Collaboration



Empower Global Biotherapeutics Innovation

- Building the Builders
- Idea to IND

CONTENTS

01 Opening Remarks

02 **Harbour Therapeutic: Innovation Empowered Growth**

03 Nona Biosciences: Platform-based Enabler from Idea to IND

04 Closing Remarks





Porustobart: Next-Gen Anti-CTLA4 Antibody with Potential to Become the Cornerstone Therapy


Dr. Humphrey Gardner

Chief Medical Officer

Harbour BioMed



Porustobart (HBM4003)

Leading Development of Next Gen Anti-CTLA-4 Therapeutics with Novel MoA



Porustobart (HBM4003)

Next-Gen Anti-CTLA-4 Antibody with Potential to be the Mainstream of IO Therapeutics




- Competitive Advantages**
- 1 Deplete intra-tumoral Treg cells via enhanced ADCC strategy
 - 2 Great safety profile resulted from the reduced drug exposure in the serum
 - 3 Huge potential for combination therapies




Selective Intratumor Treg Depletion and CD8+ Stimulation

Tumor Biopsy



Peripheral Blood




Porustobart (HBM4003)

MoA Reflected via Clinical Benefit in Chinese Melanoma Patients


Robust efficacy observed for HBM4003 + Toripalimab in PD-1 naïve melanoma cohort

Best Overall Response by RECIST 1.1, N (%)

Pts with tumor assessments	15 (100%)
CR	0 (0%)
PR	8 (53.3%)
ORR (CR + PR)	8 (53.3%)
SD	3 (20.0%)
DCR (CR + PR +SD)	11 (73.3%)
Tumor reduction	9 (60%)




HBM4003 + Toripalimab elicited the highest response rate in Chinese melanoma patients



- Preliminary data of 4003.2 study (NCT04727164), PD-1 naïve melanoma pts treated with RP2D (HBM4003 0.3mg/kg + Toripalimab 240mg Q3W) in Part 1 and Part 2
- 17 pts treated with median follow up of 105 days (range: 11-138 days), in which 15 pts had at least one post treatment tumor assessment

■ ■ ■ Porustobart (HBM4003)

■ ■ ■ Near Term Registration and Further Opportunities in Hitherto Intractable Indications




Clinical Progress and Upcoming Milestone

Neuroendocrine Carcinoma



- ✓ Patients enrollment completed in Q3 2022
- ✓ **Double** the clinical response rate from preliminary data compared with available treatments
- ✓ **Durable** clinical benefit observed in multiple patients
- ✓ Planned publication in academic conference 2023

Hepatocellular Carcinoma



- ✓ Patients enrollment completed in Q3 2022
- ✓ Demonstrated **best in class** potential from preliminary data
- ✓ Clinical benefit was observed in **heavily pre-treated** patients, frontline treatments include TKIs and anti-PD-1 antibody
- ✓ Planned publication in academic conference 2023

Porustobart **Cornerstone for new therapeutic avenues**

- ✓ Treg depletion verified in clinic
- ✓ CD8⁺ T cell increased in TME
- Threefold** improved clinical response rate vs. PD-1 monotherapy

Further established Porustobart as next generation I/O treatment in combination with anti-PD-1

Expand the IO-IO strategy through combination with internal assets

- B7 family members
 - B7H7
 - B7H4

T Cell Engagers from HBICE® Platform

Diversify through partnerships with various modalities

Expand into synergy with innovative mechanisms

- Target therapies
- Chemotherapy
- Antibody-drug conjugates
- Cell therapies

- Remodeling of tumor microenvironment
 - Treg cells
 - Myeloid cells
 - Checkpoint inhibitors



Robust Portfolio Generated from Discovery Engines

Dr. Yiping Rong

Chief Scientific Officer

Harbour BioMed



Research Strategy Leveraging HBM's Technology Platforms

1. Stimulate Immune Cells


(Immune Cell Engager, ICE)

by Immune Cell Engager Bispecific, e.g.
HBICE technology

2. Treg/Tumor Direct Killing

(TDK)

Deplete Treg cells or Tumor cells by
eADCC and next-gen ADC technology





3. Overcome Immune Suppression

Modulate alternative Immune Evasion Pathways (IEP)
beyond PD1/L1 using H2L2/HCAb/SBC technology



Harbour Therapeutics Portfolio Strategy in Periodic Table

-We Innovate Cancer Therapy in Three Oncology MoA Strongholds

Direct Killing	Stimulate Immune Cells (Immune Cell Engager)						Overcome Immune Suppression
CTLA4-eADCC HBM4003	Stimulate Immune Cells (Immune Cell Engager)						CD73 HBM1007
CCR8-eADCC HBM1022	T Cell Engager			BiKE	BiME/BiDE	T and NK	B7H7 HBM1020
CD25-eADCC HBM1039	CD3 HBICE®	4-1BB HBICE®	CD28 HBICE®	NKp30 HBICE®	CD40 HBICE®	Other HBICE®	CD200R1 HBM1047
MSLN-ADC HBM9033	BCMAxCD3 HBM7020 	B7H4x4-1BB HBM7008	PDL1xCD28 HBM7024	ROR1xNKp30 HBM7025	PDL1xCD40 HBM9027	CD122xCD132 HBM1040	SigLec-7/9 HBM1057
CEACAM-ADC HBM1053	B7H4xCD3 HBM7004	MSLNx4-1BB HBM7021			5T4xCD40 HBM7023	CRTAM HBM1054	CD36 HBM1055
	CLDN18.2xCD3 AZD5863/HBM7022 						LIFR HBM9014

HBM9014 (LIFR)

The First Antibody Targeting LIFR, a Novel Growth Factor Receptor in Multiple Tumors


Collaboration with Innuoke



Highlights


- ❑ One of the most important growth factor pathway in PDAC, CRC and prostate cancers. LIF is also a key paracrine factor from stromal cells acting on cancer cells and modulating tumor microenvironment.
- ❑ Blockage of LIFR inhibits the action of LIF and overlapping cytokines. LIFR inhibition is a potentially more efficient approach than LIF inhibition.
- ❑ Blocks both LIF and CLCF1 pathways, which expressions are significantly elevated in TME and correlate to poor prognosis
- ❑ Encouraging in vivo efficacy superior to MSC-1(anti-LIF mAb in phase II trial for PDAC) and enhanced chemo drug efficacy in preclinical models

IND 2023



MSC-1: Anti-LIF mAb (Northern Biologics/AstraZeneca)

Enhanced efficacy in combination with Cisplatin



HBM7008 (B7H4x4-1BB)

First-in-Class Bispecific Antibody from HBICE® Platform



Competitive Advantages and Highlights

- Fully human **bispecific antibody** from the HBICE® platform
- Novel immune escape pathway - **First-in-class** target (B7H4x4-1BB)
- Excellent safety profile**, potential to avoid 4-1BB liver toxicity risk with the benefit of its innovative biology mechanisms and bispecific design



Global Multi-Center Clinical Trials



Australia: Ongoing Phase I Trial




USA: Ongoing phase 1 Trial




China: Obtained IND Approval


HBM7008 completely leads tumor regression in B7H4 positive syngeneic model



'2+2' symmetric HBICE (S-HBICE)



B7H4 dependent 4-1BB activation and T cell stimulation



HBM7004 (B7H4xCD3)

Unique "2+1" Asymmetric HBICE[®] Using Novel TAA and Safer Anti-CD3 Arm




Highlights


- ❑ HBICE[®] technology grants asymmetric structure but less light chain mispairings
- ❑ TAA is mainly expressed in low PD-L1 tumors, particularly in gynecological cancers and squamous cell lung cancer
- ❑ Potentially combine with PD1 therapy or in-house HBM7008 to overcome T cell engager challenges in solid tumor

Molecule Design and MOA



Optimized anti-CD3 arm, ~200-300nM Strong bivalent binding to B7H4



Strong Anti-tumor Activity in Mouse Tumor Model



HBM7004 (Signal 1) Combined with HBM7008(Signal 2) are Critical for T Cell Engager Efficacy in Cold Solid Tumors



HBM9027 (PD-L1xCD40)


Innovative Bispecific Antibody Activating APC/T Cells




Highlights

- ❑ Synergistically activating both myeloid/DC cells and T cells is critical for some solid tumor therapy considering the most abundant myeloid cell population in TME
- ❑ Well maintained α PD-L1 arm and α CD40 arm function activity with robust developability using fully human symmetrical HBICE[®] format
- ❑ Encouraging in vivo efficacy superior to Tecentriq and safety profile is much better than Selicrelumab

Molecule Design and MOA



Strong Anti-tumor Activity in hPD-1/hCD40 DKI Mice



HBM1020 (B7H7)

Novel B7 Family Plays an Alternative Immune Escape Mechanism Beyond PD-L1




Highlights


- 1) B7H7 is a **first-in-class** target potentially serving as an alternative immune escape pathway
- 2) Potent receptor blocking, T cell activation activity and excellent in vivo efficacy in humanized tumor models
- 3) Huge potential to treat PD-L1 negative or anti-PD1/PD-L1 refractory cancer patients

IND Dec 2022

Strong Anti-tumor Activity in Breast Cancer Model



Breast Cancer Human PBMC Model



HBM1047 (CD200R1)


Novel IO Checkpoint Targets Regulating Both T Cells and Myeloid Cells



Highlights


- ❑ 1st fully human antagonistic antibody against CD200R1 for cancer therapy
- ❑ CD200R1 is highly expressed in ICI non-responders T/Myeloid cells serving as an alternative immune escape pathway
- ❑ Dual modulator for both tumor infiltrated T cells and myeloid cells with strong blocking activity and anti-tumor activity
- ❑ 1st CD200R1 antibody showing potent anti-tumor efficacy in syngeneic model with excellent monkey PK and safety profile

Molecule Design and MOA



Anti-tumor Efficacy in Syngeneic Tumor Model

MC38-mCD200 mouse syngeneic model



HBM1022 (CCR8)

Next-Gen Treg Depletion Therapeutics Targeting CCR8




Highlights

- 1) Potent tumor resident Treg depletion activity
- 2) Potent inhibition of CCL1-induced signaling pathway / in vivo anti-tumor efficacy
- 3) Comparable human/cyno binding affinity
- 4) Significant potential for breast cancer, colon cancer, and multiple solid tumors and hematological malignancies


IND Jan 2023

Function Activity and Anti-tumor Efficacy

HBM1022




1. High CCR8 expressing Tregs allow for antibody mediated depletion via ADCC




2. CCR8 blockade inhibit ligand CCL1 induced chemotaxis of Treg into TME


HBM1022 inhibits CCL1 induced β -Arrestin signaling



HBM1022 inhibits tumor growth in either mono or combo therapy



HBM Continuously Drives Innovative Portfolio and Leads the Next-Gen Therapeutics





Platform Empowering Global Innovation with Strong Growth

Mr. Weihao Xu

Chief Financial Officer and Chief Business Officer
Harbour BioMed



Significant Advancements Achieved for Global Collaborations in 2022

Product Global License-out

- HBM7022 out-license to **AstraZeneca** with total payments **US\$350 million and royalties**
- HBM9161 out-license to **CSPC** with total payments **RMB\$1,011 million and royalties**
- Commenced collaborations with **LCB, Duality Biologics** on **ADC**



Co-discovery/Co-development

- Collaborated with **Dana-Farber** to develop novel bispecific antibodies and CAR-T
- Collaborated with **Boston Children's Hospital** to develop novel antibody therapy
- Collaborated with **BioMap** to develop novel antibodies with AI technology



Joint Venture

- Incubated NK cell therapeutics, "**NK Cell Tech**" successfully completed fundraising



Platform License-out

- Certain molecules generated from HBM technology platforms were advanced into clinical stage by **Innovent Biologics**




Develop Innovative BsAb - HBM7022 (CLDN18.2xCD3)

The First Global Out-licensed Bispecific Antibody Generated by HK-listed Bio-tech



- In April 2022, HBM7022, one pre-clinical asset, was out-licensed to AstraZeneca
- In May 2022, HBM received **US\$25 million** upfront payment (total transaction value of **US\$350 million** + royalty fee)
- In July 2022, AstraZeneca and HBM teams have successfully completed HBM7022 transfer for subsequent developments




CLDN18.2 x CD3
HBICE®



HBM7022 Highlights

- 2+1 format with better activity and potential larger therapeutic window
- Low CD3 and high CLDN18.2 affinity reduce systemic exposure and increase distribution to tumor
- Silent Fc extends half-life, avoids Fc crosslinking and ADCC

MOA of HBM7022



Develop Innovative ADC Therapeutics




Unique HCAb-based ADC Platform

- ❑ Promising potency for both cold and hot tumors
- ❑ Sensitize the tumor to immunotherapy with novel targets and payloads
- ❑ Combine SM and LM advantages to expand HBM portfolio



Harbour Mice[®] ADC Ecosystem


H2L2-ADC to MSLN



- ❑ Unique fully human antibody warhead with improved binding, internalization, blocking activity and less interference by sMSLN
- ❑ The 4th generation of serum stable and tumor-specific cleavable linker with novel payload
- ❑ Superior in vivo potency and promising safety profile compared to other ADC technologies



HARBOUR
BIOMED




Further Exploration on Next-Gen NK Cell therapeutics

☐ HBM entered into a strategic collaboration with NK Cell Tech in 2021 with HCAb out-license



Dr. Zhigang Tian

- Member of Academia Europaea
- Member of Chinese Academy of Engineering



Innovative NK cell precision therapy

- Remodeling immune microenvironment, for both cold and hot tumors
- Sensitize the tumor to immunotherapy with special targets
- Unique full human CAR/ nano antibody/ engager technology

☐ In 2022, NK Cell Tech Successfully Completed fundraising of over RMB 100 million

CONTENTS

01 Opening Remarks

02 Harbour Therapeutic: Innovation Empowered Growth

03 **Nona Biosciences: Platform-based Enabler from Idea to IND**

04 Closing Remarks





HARBOUR
BIOMED



Nona Biosciences: A Platform-based Enabler from Idea to IND

Dr. Yun He

Chief Technology Officer, Nona Biosciences

Dr. Jiyong Zhang

Head of Business Development, Nona Biosciences



Nona Biosciences Empowers Global Therapeutic Innovation




Nona: Roman Goddess Who Enables Others to Succeed

Mission


Leveraging industrial leading technology platforms, Nona Biosciences is committed to provide integrated discovery solution for biotech and pharmaceutical companies from **Idea to IND (I to I)**.

Technologies

Harbour Mice®



HCAb



Talents



Global Presence



Partners


moderna®

Dragonfly

KELUN-BIOTECH
科伦博泰



Nona Provides Fully Integrated Antibody Discovery Solutions




Harbour Mice[®] - New Generation of Fully Human Antibody Platforms

Highly Effective Engine for Generating Novel Therapeutics

Industry Leading Technology Platforms


- Worldwide patent protection
- Validated by **50+** industry and academic partners
- Applied in **200+** discovery programs
- **10+** projects having entered clinical stage

- ✓ Human
- ✓ Natural
- ✓ Optimized
- ✓ Validated




Harbour Mice[®] HCAb Transgenic Mice

A Unique Human Heavy Chain Only Antibody Platform for Generation of Next-Gen Therapeutics




HCAb PLUS[™]






Nona's Technology Platforms Have Been Endorsed by Partners


moderna



Dragonfly



KELUN-BIOTECH
科伦博泰



BIOTECH
Moderna's appetite for antibody tech spurs \$6M bet on Nona's heavy chain only platform

By Nick Paul Taylor • Nov 11, 2022 07:30am

Moderna Harbour BioMed antibody messenger RNA



Nona Biosciences Enters into HCAb Based Drug Discovery Collaboration Agreement with Dragonfly Therapeutics

Published: Nov 21, 2022

"We aim to leverage Nona's fully human antibody transgenic mice platform to obtain novel antibody molecules on specific targets and strive to develop innovative ADC drug which can meet global needs better and faster."

*Dr. Junyou Ge,
CEO of Kelun Biotech*






Nona Consistently Advances Technologies to Help Our Partners

Delivery Technology




mRNA-encoding target gene as immunogen to tackle difficult targets

Protein Engineering



Combine human antibody platforms and **protein engineering** to generate multifunctional molecules

Conjugation Technology



Novel **conjugation technology** for bringing new modalities against solid tumors

Artificial Intelligence



Artificial Intelligence for accelerating antibody discovery and optimization

Utilize mRNA Technology to Tackle Difficult Immunization Projects


Target M (novel 4-TM receptor)

Challenge No qualified FACS antibody to detect target-expressing cell lines.


Solution Immunize mice with mRNA-LNP encoding M, screen antibodies suitable for FACS.

Mice Balb/c


mice immunized with mRNA of target M raised strong serum titers



Identified antibodies specifically binding to target M on cells



Utilize Ab to validate CHOK1-hu M clones




Target S (novel 2-TM receptor)

Challenge No proteins. Cell immunogens can not raise serum titers to cyno monkey S.


Solution Immunize mice with mRNA-LNP encoding S.

Mice Harbour Mice HCAB

Cell immunogen of target S did not raise serum titers to cyno monkey



HCAB mice immunized with mRNA-LNP of target S raised higher serum titers of cyno cross-reactivity



High Throughput Screening in “Single Day” by Beacon® Single B Cell Technology


Single B Cell (SBC) technology greatly shortens the workflow from months to days

> 30,000 B cells were screened in 2-3 days by SBC, and diverse sequences of fully human antibodies were retrieved.


A. Typical Hybridoma Workflow



B. Beacon® Plasma Cell Workflow



SBC	Mice	Immunogen	Cells screened	cDNA cloned	Total Sequence	Unique Sequence VH/VL pairs
#1	H2L2	Cyno MSLN	11000	151	144	126
#2	H2L2	Human MSLN	10900	(94%)	(95%)	(79%)
#3	H2L2	Cyno MSLN	11000			





Leverage Artificial Intelligence and Single B Cell Technology to Efficiently Identify Diverse HCAb Sequences for Novel Target


- Utilize single B cell technology (SBC) to identify functional antibodies for a novel target
- hyperSCREEN* combines NGS and Machine Learning to search greater sequence space
- Identify diverse sequences with excellent biological activities or molecular properties

Harbour Mice® HCAb


Beacon®




HCAbs (SBC) binding to Target



HCAbs (*hyperSCREEN*) binding to Target



Phylogenetic tree of HCAbs from different sources






Executive Summary

Integrated Discovery Solutions

- ✓ From Idea to IND
- ✓ High quality project delivery

Industry Leading Technologies

- ✓ Harbour Mice®
- ✓ Versatile applications of human HCAb



Transformational Business Models

- ✓ Open Access
- ✓ Building the Builders

Empowering Global Therapeutic Innovation

Healthy Financial Situation

Mr. Weihao Xu

Healthy Financial Situation

Revenue

Expanded Collaboration Driving Strong Revenue Growth

- ❑ Products out-licensing by Harbour Therapeutics
- ❑ Broad networks of collaboration weaved by Nona Biosciences



Operation

Optimization on Operational Efficiency & R&D Expenses

- ❑ Diversified co-development to spread R&D costs
- ❑ Organizational optimization to reduce labor costs
- ❑ Improvement on efficiency to control project costs

Cash

Strong Cash Position

- ❑ Extended cash runway for over two years
- ❑ Flexible credit facility and draw tenor

CONTENTS

- 01 Opening Remarks
- 02 Harbour Therapeutic: Innovation Empowered Growth
- 03 Nona Biosciences: Platform-based Enabler from Idea to IND
- 04 Closing Remarks






Closing Remark

Dr. Jingsong Wang

Harbour BioMed: Leading Next-Gen Biotherapeutic Innovation

Lead Next-Gen IO Therapeutics

- Global Innovation
- Worldwide Collaboration



Empower Global Innovation

- Building the Builders
- Idea to IND

Harbour BioMed: Strong Growth with Expectable Catalysts

Long-term Value

- Robust and highly differentiated portfolio
- Strong and productive global collaboration network
- Optimized capital efficiency

Near-term Catalysts (2022-2023)

- Advancing key assets into **registration trial**
- **2 new highly innovative assets** into clinical every year
- Expanding collaborations with Nona as a global innovation enabler

Value Realization

Value Creation

Value Proposition

HBM Holdings' Strong Business and Value Growth

THANK YOU

